We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Roche Recognizes med fusion as a Molecular Center of Excellence

By LabMedica International staff writers
Posted on 06 Jun 2012
Roche Diagnostics (Roche; Basel, Switzerland), a biotech company focused on research-based healthcare, has formed an alliance with med fusion LLC (Lewisville, Texas, USA), an integrated laboratory and clinical trials service organization, designating the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.

Established in 2002, Roche's MCOE program allows noncompeting regional laboratories across the United States to collaborate and capitalize on molecular testing instruments in order to advance test methodologies and technology.

As a nationally recognized Roche MCOE, med fusion's molecular diagnostics laboratory will offer healthcare professionals and patients some of the latest and most advanced molecular technologies, including Roche's cobas 4800 BRAF V600 Mutation Test, a companion diagnostic that identifies patients who are eligible for treatment with the ZELBORAF (vemurafenib) drug for inoperable or metastatic melanoma, a deadly form of skin cancer.

"Roche is very pleased to welcome med fusion into the Molecular Center of Excellence alliance," said Whitney Green, senior vice president, molecular diagnostics, Roche Diagnostics Corporation. "We value their expertise and look forward to working together in implementing molecular technologies in the advancement of personalized medicine."

med fusion is one of 35 labs in the United States and 3 in Texas that have received this accolade. According to Dr. Thomas Lohmann, chief medical officer, med fusion, the partnership with Roche will help the company provide healthcare professionals and patients with improved diagnostic services.

"This relationship with Roche will help keep med fusion on the leading edge of technology and help ensure that we are supporting physicians and patients with the most advanced molecular technologies," added Dr. Lohmann.

Roche is an industry leader in pharmaceuticals and diagnostics, providing a broad range of products and services for the early detection, prevention, diagnosis, and treatment of diseases.



Related Links:

Roche Diagnostics

med fusion


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
New
Herpes Virus Test
Human Herpes Virus (HHV-6) Real Time PCR Kit

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests